Cassava Sciences Inc
Geschlossen
BrancheGesundheitswesen
2.1
Übersicht
Veränderung der Aktienkurses
24h
Min
2.1
Max
2.1
Einkommen | -1.7M -13M |
|---|---|
Verkäufe | 840K 840K |
Gewinnspanne | -1,492.738 |
Angestellte | 30 |
EBITDA | -39M -50M |
Marktkapitalisierung | -4.3M 142M |
|---|---|
Vorheriger Eröffnungskurs | 2.1 |
Vorheriger Schlusskurs | 2.1 |
Technischer Score
By Trading Central
Vertrauen
Weak Bearish Evidence
Cassava Sciences Inc Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
Cassava Sciences Inc Prognose
Finanzen
$
Über Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.